Stories from Darmstadt

16.09.2021 – 15:00

Fraunhofer-Institut für Sichere Informationstechnologie SIT

Study: IT security for electric cars in China

more
15.07.2021 – 16:02

IG Passivhaus

2
Reliable climate protection with Passive House

more
10.06.2021 – 11:17

Messe Erfurt

Get a glimpse of the near and distant future of additive manufacturing

Visit us on!
One document
more
17.05.2021 – 14:00

Merck Serono GmbH
Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity

Darmstadt, Germany (ots/PRNewswire) - - Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years - Call for application for a global crowdsourcing project, 'Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging' Merck, a leading science and ...

more
18.03.2021 – 10:06

Öko-Institut e.V.
Land use in the EU Climate Target Plan 2030: Ecosystems are more than carbon reservoirs

The management of forests, cropland and grassland impacts on the amount of greenhouse gases in the atmosphere. These activities must therefore be taken into account in the EU's Climate Target Plan. The EU Parliament and the European Council are currently arguing about the "how". The outcome of this ...
One document
more
16.03.2021 – 08:00

Merck Serono GmbH
Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - Not intended for US-, Canada- or UK-based media Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or ...

more
15.03.2021 – 14:20

hubergroup Deutschland GmbH

3
Press Release - Extended production possibilities: hubergroup presents LED UV inks for newspaper presses

More about hubergroup
One document
more
25.02.2021 – 14:01

Merck Serono GmbH
New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines

Darmstadt, Germany (ots/PRNewswire) - MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine ...

more
11.12.2020 – 14:33

Öko-Institut e.V.
Further design of EU climate target for 2030 decisive for climate protection

Press release Freiburg/Berlin, 11 December 2020 Further design of EU climate target for 2030 decisive for climate protection Just in time for the fifth anniversary of the Paris Climate Change Agreement, the European Council has decided to tighten the EU's climate targets. By 2030, the EU is to reduce ...
One document
more
26.11.2020 – 17:37

Merck Serono GmbH
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations

Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial ...

more
09.11.2020 – 14:07

Merck Serono GmbH
Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Merck out-licenses Phase IIb-ready atacicept to Vera Therapeutics - Phase IIa trial conducted by Merck shows promising results in IgA nephropathy (IgAN), also known as "Berger's disease" - Out-licencing deal includes 10% equity in Vera Therapeutics and up to EUR 605 million in development ...

more
07.10.2020 – 13:39

REO AG

2
REO supports Formula Student Germany - for an all-electric future with DART Racing Team

more
06.10.2020 – 14:00

Merck Serono GmbH
Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis

Darmstadt, Germany (ots/PRNewswire) - - Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® programis Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of EUR 50 million with the potential of ...

more
14.09.2020 – 00:05

Merck Serono GmbH
Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020

Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer · Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib? from ...

more
11.09.2020 – 14:00

Merck Serono GmbH
New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety

Darmstadt, Germany (ots/PRNewswire) - In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical ...

more
10.09.2020 – 14:00

Merck Serono GmbH
Merck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Sonelokinab is an investigational IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F - Phase II study was facilitated by Avillion as part of an innovative co-development model Merck, a leading science and technology company, ...

more
09.09.2020 – 12:35

Technische Universität München
P-ONE: a new, large-scale Neutrino Observatory in the Pacific Ocean

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36220/ High resolution images: https://mediatum.ub.tum.de/1574295 NEWS RELEASE Revealing the secrets of high-energy cosmic particles P-ONE: Initiative for a new, large-scale Neutrino Observatory in the Pacific ...

more
03.09.2020 – 14:00

Merck Serono GmbH
Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib - New long-term data and real-world evidence further characterise efficacy and safety ...

more
28.08.2020 – 15:51

Deutsche Post DHL Group

2
PM: Kreativwettbewerb von Deutsche Post DHL Group: Siegerentwürfe zur Gestaltung des Beethoven-Packsets stehen fest

more
13.07.2020 – 20:03

Merck Serono GmbH
Stephan Sieber Awarded EUR 1 Million Future Insight Prize 2020 by Merck

Darmstadt, Germany (ots/PRNewswire) - - Prof. Sieber is developing approaches against multi-resistant pathogens at the Technical University of Munich - Inaugural Johann Anton Merck Award presented to Prof. Caroline Dive, Cancer Research UK, for her liquid biopsy research - Sibel Health awarded the Nature Spinoff Prize Merck, a leading science and technology company, ...

more
28.05.2020 – 10:00

Merck Serono GmbH
Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS

Darmstadt, Germany (ots/PRNewswire) - - Merck and Twitch collaborate on World MS Day to increase understanding of the impact of multiple sclerosis (MS) - Livestream event with Twitch influencers on May 30 will raise awareness and money for the MS International Federation and help connect people affected by the disease, in line with official World MS Day theme MS ...

more
14.05.2020 – 11:04

Öko-Institut e.V.
Close gap in the law to improve environmental standards in online shopping

Press release Freiburg/Berlin, 14 May 2020 Close gap in the law to improve environmental standards in online shopping Some sellers of electronic equipment from non-EU countries such as China who market their products on the Internet do not contribute to the costs incurred in Germany for the collection ...
One document
more
14.05.2020 – 00:23

Merck Serono GmbH
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020

Darmstadt, Germany (ots/PRNewswire) - - Results from two studies of BAVENCIO® to be featured in ASCO press briefing - Primary efficacy, biomarker and HRQoL analyses for tepotinib?, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations - Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa? ...

more
30.04.2020 – 14:00

Merck Serono GmbH
Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care

Darmstadt, Germany and New York (ots/PRNewswire) - - Not intended for US-, Canada- or UK-based media - ASCO Abstract # BAVENCIO® (avelumab): LBA1, 5061; Bintrafusp alfa (bifunctional fusion protein): 9558; Tepotinib (MET kinase inhibitor): 9556, 9575. - Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in ...

more
02.03.2020 – 08:01

Merck Serono GmbH
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...

more
27.11.2019 – 11:27

Fraunhofer-Institut für Sichere Informationstechnologie SIT
New Award for excellent Cybersecurity Research / Fraunhofer CyberStar Award selects the best theses

Darmstadt (ots) - The Fraunhofer Institute for Secure Information Technology SIT launches the CyberStar Award for Excellent Research Students to promote graduates and students in applied cybersecurity and privacy in Israel. The Fraunhofer CyberStar Award recognizes outstanding theses with a cash prize up to 5000 USD ...

more
20.11.2019 – 08:01

Merck Serono GmbH
Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations

Darmstadt, Germany (ots/PRNewswire) - - Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in ...

more
05.11.2019 – 14:22

Fraunhofer-Institut für Sichere Informationstechnologie SIT

Fraunhofer SIT Finds Serious Security Flaws in TwitterKit for iOS

more
30.10.2019 – 19:08

Technische Universität München
Insect decline more extensive than suspected

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35768/ High resolution images: https://mediatum.ub.tum.de/1522699 NEWS RELEASE Insect decline more extensive than suspected Causes of insect decline and biodiversity loss to be found at the landscape level ...

more
28.10.2019 – 19:00

Merck Serono GmbH
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen ...

more

1234567Next